IL-27 suppresses RANKL expression in CD4+ T cells in part through STAT3

Immunology Letters

Volumn 138, Issue 1, 2011, Pages 47-53

  Kamiya, Sadahiro ^a   Okumura, Masae ^b   Chiba, Yukino ^b   Fukawa, Takeshi ^a   Nakamura, Chika ^a   Nimura, Noriyuki ^b   Mizuguchi, Junichiro ^a,b   Wada, Seiki ^a   Yoshimoto, Takayuki ^b  

^a JOSAI INTERNATIONAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

CD4+ T cells; IL 27; RANKL; STAT3

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 27; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; STAT3 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CELL SURFACE; CONTROLLED STUDY; CYTOKINE PRODUCTION; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; T LYMPHOCYTE ACTIVATION; TH17 CELL;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELLS, CULTURED; GENE EXPRESSION REGULATION; INTERLEUKINS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; RANK LIGAND; RECEPTORS, ANTIGEN, T-CELL; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR;

EID: 79957694768     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2011.02.022     Document Type: Article

References (39)

1. Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M., et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997, 272:25190-25194.
2. Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997, 390:175-179.
3. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
4. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998, 95:3597-3602.
5. Pettit A.R., Ji H., von Stechow D., Muller R., Goldring S.R., Choi Y., et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001, 159:1689-1699.
6. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
7. Dai S.M., Nishioka K., Yudoh K. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha. Ann Rheum Dis 2004, 63:1379-1386.
8. Horwood N.J., Kartsogiannis V., Quinn J.M., Romas E., Martin T.J., Gillespie M.T. Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun 1999, 265:144-150.
9. Wang R., Zhang L., Zhang X., Moreno J., Celluzzi C., Tondravi M., et al. Regulation of activation-induced receptor activator of NF-kappaB ligand (RANKL) expression in T cells. Eur J Immunol 2002, 32:1090-1098.
10. Nakashima T., Kobayashi Y., Yamasaki S., Kawakami A., Eguchi K., Sasaki H., et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 2000, 275:768-775.
11. Pflanz S., Timans J.C., Cheung J., Rosales R., Kanzler H., Gilbert J., et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002, 16:779-790.
12. Yoshida H., Nakaya M., Miyazaki Y. Interleukin 27: a double-edged sword for offense and defense. J Leukoc Biol 2009, 86:1295-1303.
13. Sato K., Suematsu A., Okamoto K., Yamaguchi A., Morishita Y., Kadono Y., et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006, 203:2673-2682.
14. Niedbala W., Cai B., Wei X., Patakas A., Leung B.P., McInnes I.B., et al. Interleukin 27 attenuates collagen-induced arthritis. Ann Rheum Dis 2008, 67:1474-1479.
15. Furukawa M., Takaishi H., Takito J., Yoda M., Sakai S., Hikata T., et al. IL-27 abrogates receptor activator of NF-kappa B ligand-mediated osteoclastogenesis of human granulocyte-macrophage colony-forming unit cells through STAT1-dependent inhibition of c-Fos. J Immunol 2009, 183:2397-2406.
16. Takeda K., Kaisho T., Yoshida N., Takeda J., Kishimoto T., Akira S. Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J Immunol 1998, 161:4652-4660.
17. Takahama Y., Ohishi K., Tokoro Y., Sugawara T., Yoshimura Y., Okabe M., et al. Functional competence of T cells in the absence of glycosylphosphatidylinositol-anchored proteins caused by T cell-specific disruption of the Pig-a gene. Eur J Immunol 1998, 28:2159-2166.
18. Robertson J.M., Jensen P.E., Evavold B.D. DO11.10 and OT-II T cells recognize a C-terminal ovalbumin 323-339 epitope. J Immunol 2000, 164:4706-4712.
19. Fischer M., Goldschmitt J., Peschel C., Brakenhoff J.P., Kallen K.J., Wollmer A.I., et al. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol 1997, 15:142-145.
20. Matsui M., Moriya O., Belladonna M.L., Kamiya S., Lemonnier F.A., Yoshimoto T., et al. Adjuvant activities of novel cytokines, interleukin-23 (IL-23) and IL-27, for induction of hepatitis C virus-specific cytotoxic T lymphocytes in HLA-A 0201 transgenic mice. J Virol 2004, 78:9093-9104.
21. Kamiya S., Owaki T., Morishima N., Fukai F., Mizuguchi J., Yoshimoto T. An indispensable role for STAT1 in IL-27-induced T-bet expression but not proliferation of naive CD4+ T cells. J Immunol 2004, 173:3871-3877.
22. Kong Y.Y., Feige U., Sarosi I., Bolon B., Tafuri A., Morony S., et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402:304-309.
23. Takayanagi H., Ogasawara K., Hida S., Chiba T., Murata S., Sato K., et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000, 408:600-605.
24. Stumhofer J.S., Silver J.S., Laurence A., Porrett P.M., Harris T.H., Turka L.A., et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol 2007, 8:1363-1371.
25. Fitzgerald D.C., Zhang G.X., El-Behi M., Fonseca-Kelly Z., Li H., Yu S., et al. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol 2007, 8:1372-1379.
26. Batten M., Kljavin N.M., Li J., Walter M.J., de Sauvage F.J., Ghilardi N. Cutting edge: IL-27 is a potent inducer of IL-10 but not FoxP3 in murine T cells. J Immunol 2008, 180:2752-2756.
27. Owaki T., Asakawa M., Morishima N., Mizoguchi I., Fukai F., Takeda K., et al. STAT3 is indispensable to IL-27-mediated cell proliferation but not to IL-27-induced Th1 differentiation and suppression of proinflammatory cytokine production. J Immunol 2008, 180:2903-2911.
28. Awasthi A., Carrier Y., Peron J.P., Bettelli E., Kamanaka M., Flavell R.A., et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol 2007, 8:1380-1389.
29. Ernst C.W., Lee J.E., Nakanishi T., Karimbux N.Y., Rezende T.M., Stashenko P., et al. Diminished forkhead box P3/CD25 double-positive T regulatory cells are associated with the increased nuclear factor-kappaB ligand (RANKL+) T cells in bone resorption lesion of periodontal disease. Clin Exp Immunol 2007, 148:271-280.
30. Kotake S., Udagawa N., Hakoda M., Mogi M., Yano K., Tsuda E., et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001, 44:1003-1012.
31. Miranda-Carus M.E., Benito-Miguel M., Balsa A., Cobo-Ibanez T., Perez de Ayala C., Pascual-Salcedo D., et al. Peripheral blood T lymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin-15 on the cell surface and promote osteoclastogenesis in autologous monocytes. Arthritis Rheum 2006, 54:1151-1164.
32. Crotti T.N., Smith M.D., Weedon H., Ahern M.J., Findlay D.M., Kraan M., et al. Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 2002, 61:1047-1054.
33. Bendixen A.C., Shevde N.K., Dienger K.M., Willson T.M., Funk C.D., Pike J.W. IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1. Proc Natl Acad Sci USA 2001, 98:2443-2448.
34. Abu-Amer Y. IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. J Clin Invest 2001, 107:1375-1385.
35. Wei S., Wang M.W., Teitelbaum S.L., Ross F.P. Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kappa B and mitogen-activated protein kinase signaling. J Biol Chem 2002, 277:6622-6630.
36. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 Cells. Annu Rev Immunol 2009, 27:485-517.
37. McGeachy M.J., Bak-Jensen K.S., Chen Y., Tato C.M., Blumenschein W., McClanahan T., et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007, 8:1390-1397.
38. Liu D., Yao S., Wise G.E. Effect of interleukin-10 on gene expression of osteoclastogenic regulatory molecules in the rat dental follicle. Eur J Oral Sci 2006, 114:42-49.
39. Ju J.H., Cho M.L., Moon Y.M., Oh H.J., Park J.S., Jhun J.Y., et al. IL-23 induces receptor activator of NF-kappaB ligand expression on CD4+ T cells and promotes osteoclastogenesis in an autoimmune arthritis model. J Immunol 2008, 181:1507-1518.